U.S. Markets closed

JGR Capital Partners Initiates Coverage on BioCorRx Inc. with a Price Target of $0.09

NEW YORK, NY / ACCESSWIRE / January 19, 2017 / JGR Capital Partners, a leading equity research and digital investor relations firm, has announced it has initiated coverage on BioCorRx (OTC PINK: BICX) with a price target of $0.09.

The full report can be found here: BICX Initiation

BioCorRx operates in the addiction and rehabilitation industry. The company's main product is the BioCorRx recovery program, a comprehensive addiction treatment plan. Recently, BioCorRx has seized upon a new opportunity to develop injectable Naltrexone treatments through its BioCorRx Pharmaceuticals division. BioCorRx is a unique investment opportunity with strong potential for growth within the addiction and rehabilitation industry.

Alcohol and illicit drugs are projected to result in a $41 billion cost to the U.S. healthcare system, according to the 2016 Forbes article, "Inside the 35 Billion Addiction Treatment Industry." Behavioral health treatment within the United States is also a large market, with approximately $50 billion spent each year, according to the 2014 Harris Williams article, "Behavioral Health Market Overview." BioCorRx looks ready to seize market share within these expanding markets.

Key Report Highlights:

BioCorRx is developing a new injectable form of Naltrexone with potential to replace Alkermes' Vivitrol

BioCorRx's largest and most direct competitor is Alkermes (ALKS). Alkermes markets Vivitrol, an FDA-approved injection of Naltrexone. Vivitrol is projected to generate roughly $200 million in sales for 2016, which provides an enormous growth opportunity for BioCorRx.

BioCorRx recently received $2.5 million investment

BioCorRx received a $2.5 million from private equity firm Alpine Creek Capital. This is the single largest investment made in the company thus far and we view this as a strong indicator of BICX's investment merits, given the intense due diligence performed prior to investment.

We initiate coverage on BioCorRx with a price target of $0.09

To value BioCorRx, we used a blended valuation consisting of a discounted cash flow model (DCF), comparable company analysis, and precedent merger and acquisition transactions. Based on the three valuation metric,s we have set a price target of $0.09 for BioCorRx.

Disclosures pertaining to this report can be found at www.jgrcapitalpartners.com.

About BioCorRx Inc:

BioCorRx is an addiction treatment company offering a unique approach to substance abuse. The BioCorRx Recovery Program is a non-addictive medication-assisted program consisting of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers non-addictive medication Naltrexone, an opioid antagonist that can significantly reduce cravings for opioids and alcohol. The second component developed by the company is a one-on-one proprietary counseling program specifically tailored for treating alcoholism and substance abuse disorders. More information on BioCorRx can be found at www.biocorrx.com.

About JGR Capital Partners:

JGR Capital Partners is an international equity research and digital investor relations firm that focuses on companies under $2 billion in market capitalization. The firm is headquartered in New York City, with affiliate offices in Los Angeles, Sao Paulo, and Shanghai. Our team of experienced analysts form investment theses based on company and sector expertise, with a strict focus on fundamentals and valuation. For more information on JGR Capital Partner's, visit our website at www.jgrcapitalpartners.com.

Contact Information:

JGR Capital Partners: research@jgrcapitalpartners.com

SOURCE: JGR Capital Partners